The company’s chief executive officer Adar Poonawalla said the prevailing strain of COVID-19 is mild and the Serum Institute of India (SII) has produced five to six million doses of the Covax vaccine.
The company’s chief executive officer Adar Poonawalla said the prevailing strain of COVID-19 is mild and the Serum Institute of India (SII) has produced five to six million doses of the Covax vaccine.